Pfizer Ltd.
Snapshot View

5885.50 +44.40 ▲0.8%

30 July 2021, 04:00:00 P.M.
Volume: 3,124

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.pfizerindia.com
Financial Indicators
Market Cap 26,858.49 Cr.
Earnings per share (EPS) 125.27 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 46.87 Trailing Twelve Months Ending 2021-06
Industry PE 35.15 Trailing Twelve Months Ending 2021-06
Book Value / Share 566.79 Trailing Twelve Months Ending 2021-06
Price to Book Value 10.36 Calculated using Price: 5,871.00
Dividend Yield 0.60 Period Ending 2021-03
No. of Shares Subscribed 4.57 Cr. 45,747,732 Shares
FaceValue 10
Company Profile

Pfizer is a Public Limited Company, incorporated under the Indian Companies Act, 1913, having its registered office in Mumbai, Maharashtra and is listed on the BSE Limited and the National Stock Exchange of India Limited

Pfizer scientists have produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. The company is taking on some of the world's most difficult diseases, including cancer, arthritis, and osteoporosis.

Business area of the company

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Awards

2001

  • OPPI Brand Excellence Award for Minipress XL.

2002

  • Express Pharma Biz Award for overall performance.
  • Rated as one of India's most socially responsive companies. Awarded by FICCI-Socio Economic Development Foundation for our Social Responsiveness.

2003

  • Voted as the 5 'Most Respected Company' in the Pharma sector (Business World).
  • Corporate Advertising Campaign won a Silver Award at the ABBY-All India Awards for Creative Excellence. Gelusil brand received a Silver Award for printing advertising.
  • Golden Peacock National Training Special Commendation for Training practices.

2004

  • Ranked 5 among all pharmaceutical companies, with respect to corporate image, field-force, and promotional programs (AC Nielsen-ORG Marg 'Corporate Image Survey').
  • Ranked 1 among all Pharma MNCs & 4 among all Pharma Companies by Business World.
  • Kewal Handa, CFO Pfizer Limited receives the ‘India CFO 2004 - Excellence in Finance in an MNC’ by International Market - Assessment Group.

2005

  • Golden Peacock Innovative Service Award for Prime MD Today (Daxid).
  • PC Quest 'Best IT Implementation Users Choice' award for OPTILEARN.
  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and #3 among all pharmaceuticals, in the Business World survey.

2006

  • Pharma Excellence Awards 2006 in 'Innovative Products of the Year' category for Exubera.
  • Ranked 1 among multinationals and 3 among all pharmaceuticals, in the Business World survey.
  • Kewal Handa, Managing Director Pfizer, awarded the Bharat Shiromani award for his outstanding contribution in the pharmaceutical industry.

2007

  • Reader’s Digest Trusted Brand Asia - Gold Award 2007’ in the vitamin and health supplement category for Becosules.

2008

  • Frost & Sullivan Brand Strategy Leadership Award for Becosules in the Indian Dietary Supplement Market.
  • Pfizer India was recently conferred the ‘Innovative Training Practices’ Award for promoting effective and optimum utilization of human resource through education and training by the Indian Society for Training and Development (ISTD).

2009

  • Pfizer Limited (India) conferred the Multinational Pharmaceutical Company of the Year by Frost & Sullivan.

2010

  • Pfizer Limited awarded the Most Admired Pharmaceutical Company of the Year by Pharma Leaders Magazine.
  • Kewal Handa, Country Manager - Pfizer Limited recognized as Pharma Professional of the Year by Pharma Leaders Magazine.
  • Pfizer wins the Community Engagement Award at the Asia Responsible Entrepreneurship Awards 2010 in India.

2011

  • Pfizer India has been recognized as one of The Best Companies to Work For by Business Today magazine.

2012

  • J.D. Power and Associates has honored the MS LifeLines call center with certification for an outstanding customer service experience. This is the first time J.D. Power has recognized a pharmaceutical call center. Click Here.

2013

  • GBCHealth Business Leadership Award - in recognition for the Global Health Fellows program. This award is given annually to a company or business leader with a deep and long-term commitment to global health that extends beyond the business objective of the company itself. Caroline Roan will be accepting the award on behalf of Pfizer.
  • Business Action on Health Award in Application of Core Competence for Global Health Fellows Program (commendation). Oonagh Puglisi will be accepting the award for the GHF program.
  • Business Action on Health Award in Partnership/Collective Action for Advancing Cancer & Tobacco Control in China Program. Danlong Feng, Corporate Affairs Director, Pfe China, will be accepting the award.
  • QUESTAR Award - The International Awards Festival for Excellence in Video Communications Pfizer was awarded the Grand -- best of category -- in Annual Reports in the 2013 Questar Awards.
  • Telly Award - For over a quarter century, the Telly statuette has been a symbol of creative excellence. Pfizer was awarded - Bronze at the 2013 Telly's for online videos.

Milestones:

  • 1849: Charles Pfizer & Company established. 1' product for treatment of intestinal worms is a success.
  • 1880: Pfizer manufactures Citric Acid. Rapid growth on the back of aerated drinks demand.
  • 1882: Alexander Fleming discovers penicillin.
  • 1944: Pfizer finds a way to mass-produce Penicillin.
  • 1950: Terramycin, the 1st pharmaceutical sold in the US under the Pfizer label.
  • 1950: India operation launched, with HQ in Mumbai.
  • 1966: Pfizer listed on the Bombay Stock Exchange.
  • 1989: Dolonex (Feldene) launched in India.
  • 1993: Amlogard (Norvasc) launched in India.
  • 1996: Launch of MinipressXL, an anti hypertensive drug.
  • 1998: Launch of Viagra, for erectile dysfunction.
  • 1999: Pfizer listed on the National Stock Exchange.
  • 2000: Launch of Magna& a unique hospital antibiotic.
  • 2002: Futuristic tablet manufacturing Goa plant commissioned in a record 13 months.
  • 2003 Completes merger with Parke-Davis (India) Ltd.
  • 2005: Announces merger with Pharmacia Healthcare ltd.
  • 2006: Launch of LYRICA (pregaballn for treatment of neuropathic pain)
  • 2008: Launch of Champix - a non-nicotine smoking cessation prescription drug.
  • 2010: Launch of Prevenar 13, vaccine for prevention of pneumococcal disease and included later in India’s Universal Immunization Programe.
  • 2015: Completed merger with Wyeth Limited.
  • 2016: Launched Xeljanz-the first oral Janus Kinase (JAK) inhibitor.
  • 2017: Acquires 2 breakthrough brands- Meronem, Neksium.
  • 2019: Reorganizes into 3 distinct business units: Pfizer Biopharma Group, UpJohn and Consumer Healthcare. New purpose and values unveiled.
  • 2019: Launches novel anti-bacterial Zavicefta in India.
  • 2020: Launch of Zinforo, a noval cephalosporin indicated for treatment of adult patients with community- acquired Pneumonia.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.76%
1 Week
+4.60%
1 Month
+3.80%
3 Month
+11.64%
6 Month
+26.90%
1 Year
+39.08%
2 Year
+86.71%
5 Year
+194.96%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 33.56 18.77 5.31 14.75 14.70 14.11 15.07 15.89 17.19
Return on Capital Employed (%) 46.38 28.96 15.87 22.78 22.62 21.49 23.22 20.38 23.62
Return on Assets (%) 28.24 14.91 4.00 11.22 10.95 10.36 11.25 12.20 13.00

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 1,694 658 1,973 2,164 2,419 2,683 3,011 3,395 2,393
Non Curr. Liab. -26 -19 -35 66 62 52 37 136 85
Curr. Liab. 351 303 609 658 780 954 892 873 774
Minority Int.
Equity & Liab. 2,020 942 2,547 2,888 3,261 3,690 3,940 4,405 3,252
Non Curr. Assets 215 257 1,295 1,256 1,210 1,273 1,225 1,357 1,328
Curr. Assets 1,804 686 1,252 1,632 2,051 2,417 2,715 3,048 1,925
Misc. Exp. not W/O
Total Assets 2,020 942 2,547 2,888 3,261 3,690 3,940 4,405 3,252

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1,049 1,112 1,853 2,012 1,966 1,969 2,082 2,152 2,239
Other Income 105 109 72 87 101 114 167 184 81
Total Income 1,154 1,221 1,925 2,099 2,067 2,083 2,249 2,336 2,320
Total Expenditure -865 -873 -1,474 -1,579 -1,616 -1,468 -1,516 -1,579 -1,526
PBIDT 289 349 451 520 451 615 733 757 794
Interest -2 -1 -2 -1 -2 -1 -2 -11 -15
Depreciation -8 -8 -131 -58 -63 -66 -71 -103 -109
Taxation -191 -119 -138 -165 -180 -188 -231 -133 -171
Exceptional Items 414 -111 10 130
PAT 503 221 70 305 337 360 429 509 498

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -16 132 113 345 329 332 98 323 427
Cash Fr. Inv. 626 103 -89 -701 -250 -238 35 1,530 -469
Cash Fr. Finan. -43 -1,360 -1 -62 -83 -110 -110 -164 -1,571
Net Change 567 -1,125 23 -417 -3 -17 23 1,690 -1,613
Cash & Cash Eqvt 1,433 308 488 71 68 51 74 1,764 151

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92 63.92
Public 36.08 36.08 36.08 36.08 36.08 36.08 36.08 36.08 36.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 please find enclosed a copy of the newspaper advertisement inter-alia
informing about the Notice of the 70th Annual General Meeting of the Company along with the details of the remote e-voting facility and e-voting at the AGM and Book Closure Dates published in the Business Standard (English) and Sakaal (Marathi) on July 29 2021.

We request you to kindly take the above on record.
Wed, 28 Jul 2021
Unaudited Financial Results For The Quarter Ended June 30 2021.
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we submit herewith the unaudited financial results for the quarter ended June 30 2021 which were approved by the Board of Directors of the Company at its Meeting held today that commenced at 11.30 a.m. and concluded at 2.00 p.m.

Also please find enclosed the Limited Review Report by our Auditors M/s. Walker Chandiok & Co LLP in respect of the above results.

Please take the above on record.
Wed, 28 Jul 2021
PFIZER LIMITED - IMPORTANT COMMUNICATION FOR SHAREHOLDERS - 70TH ANNUAL GENERAL MEETING AND PAYMENT OF DIVIDEND.
PFIZER LIMITED - IMPORTANT COMMUNICATION FOR SHAREHOLDERS - 70TH ANNUAL GENERAL MEETING AND PAYMENT OF DIVIDEND.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%